Parametric Portfolio Associates’s ImmunityBio IBRX Stock Holding History

Parametric Portfolio Associates’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$247K	Sell	44,054 -10,930	-20%	-$67.1K	﹤0.01%	3359
2021 Q4	$334K	Buy	54,984 +29,292	+114%	+$220K	﹤0.01%	3240
2021 Q3	$250K	Buy	25,692 +5,069	+25%	+$55.8K	﹤0.01%	3367
2021 Q2	$294K	Buy	20,623 +7,281	+55%	+$120K	﹤0.01%	3279
2021 Q1	$317K	Buy	+13,342	New	+$346K	﹤0.01%	3695
2019 Q3	–	Sell	-36,719	Closed	-$37K	–	3964
2019 Q2	$37K	Buy	+36,719	New	+$42.4K	﹤0.01%	3928
2018 Q4	–	Sell	-27,185	Closed	-$101K	–	3931
2018 Q3	$101K	Buy	27,185 +9,692	+55%	+$30.6K	﹤0.01%	3846
2018 Q2	$54K	Buy	17,493 +4,012	+30%	+$14.9K	﹤0.01%	3844
2018 Q1	$52K	Buy	13,481 +1,976	+17%	+$8.66K	﹤0.01%	3903
2017 Q4	$52K	Buy	+11,505	New	+$54.5K	﹤0.01%	3866
2017 Q3	–	Sell	-25,954	Closed	-$197K	–	4038
2017 Q2	$197K	Buy	+25,954	New	+$112K	﹤0.01%	3820

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parametric Portfolio Associates's IBRX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its ImmunityBio (IBRX) stake by 20% in Q1 2022, selling an estimated $67.1K and leaving 44,054 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #3359.

Parametric Portfolio Associates first reported a position in IBRX in Q2 2017 and has held it in 11 quarters since. The position peaked at $334K in Q4 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

Parametric Portfolio Associates held 44,054 shares of ImmunityBio worth $247K as of Q1 2022.
Parametric Portfolio Associates sold 10,930 ImmunityBio shares in Q1 2022, an estimated $67.1K.
ImmunityBio made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3359 holding.
Parametric Portfolio Associates first reported a position in ImmunityBio in Q2 2017 and has held it in 11 quarters since.
Parametric Portfolio Associates's ImmunityBio position peaked at $334K in Q4 2021.
149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.